Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...